

# 8<sup>th</sup> Asia Partnership Conference of Pharmaceutical Associations (APAC) CONFERENCE

Tokyo, 9<sup>th</sup> April 2019

# 1. Why did your economy hold GRM?

✓ What did you expect for GRM at the beginning?



## IMPLEMENTATION OF GOOD REGISTRATION MANAGEMENT



# GRM Practice in Indonesia



## Good Review Practices

- Timeliness
- Predictability
- Consistency
- Transparency
- Clarity
- Efficiency
- High quality



## Good Submission Practices

- Strong scientific rationale and robust data with clarification of benefit-risk profile
- Compliance to Up to date Regulatory Requirements
- Well structured submission dossier with appropriate cross references
- reliability, quality, integrity, and traceability of information and data
- Effective and Efficient Communications

# GRev Practice in Badan POM



Increase quality and quantity of the human resource.

Establishment of procedure and timeline for evaluation.

Using national & international standard for evaluation.

Implementation of QMS.

Establish SOP for evaluation process and decision making.

Establishing mechanism for communication with stakeholders.

Develop electronic registration.

Maintain conflict of interest and confidentiality through out the evaluation process and decision making.



- The same standard used for evaluation.
- Good quality evaluation result.
- Condition of country and regulation.
- Transparency
- Trust.
- Understanding of the system.



**What was improved by GRM implementation?**





# Better Communication with Stakeholder

## Focus Grup Discussion on Drug Registration, 6<sup>th</sup> June 2014

- To have the same perception about drug registration requirements and evaluation timeline between NADFC and Industry

## 2nd Focus Grup Discussion on Drug Registration, 4<sup>th</sup> March 2015

- As a follow-up to the 1st meeting and to discuss any issues regarding drug registration requirements and evaluation timeline

## Workshop Regulatory, 14-15 December 2016

- Discuss registration issues (case study) as well as launching and socialization of IND, Biosimilar and Good Clinical Practice Guideline

## FGD , December 2018

- Discuss registration issues to develop “a pre-market simplification”



# To make better Communication with Stakeholder

Training of Good Submission Practice, June 2019

- To have the same perception about drug registration requirements and evaluation timeline between NADFC and Industry

..... Routine consultation desk.....

.....





- Provide clear, un-ambiguous and feasible regulation
- Good resources.
- Efficient system and mechanism for registration.
- Transparency in process and decision making.
- Good communication between regulatory authority and stakes holder.
- Periodic Review on the registration management.

*Thank You!*

Terima  
kasih

